Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spontaneous Haematomas of Psoas Occurring in Intensive Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03452631
Recruitment Status : Unknown
Verified February 2018 by University Hospital, Strasbourg, France.
Recruitment status was:  Recruiting
First Posted : March 2, 2018
Last Update Posted : July 6, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Psoas hematomas are a rare and potentially lethal pathology whose incidence in resuscitation is unknown. The pathophysiology of this pathology is not known to date.

Condition or disease
Psoas Hematomas

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Spontaneous Haematomas of Psoas Occurring in Intensive Care: Incidence, Patient Characteristics and Treatment, a Retrospective Study
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of psoas hematomas [ Time Frame: 72 hours after admission to intensive care ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with psoas hematoma diagnosed during hospitalization
Criteria

Inclusion Criteria:

  • Major patients
  • Psoas hematoma diagnosed during hospitalization

Exclusion Criteria:

  • Refusal to participate in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03452631


Contacts
Layout table for location contacts
Contact: Julie HELMS, MD 33 3 69 55 13 69 julie.helms@chru-strasbourg.fr
Contact: Thierry ARTZNER, MD 33 3 69 55 13 69 Thierry.artzner@chru-strasbourg.fr

Locations
Layout table for location information
France
Service de Réanimation médicale Recruiting
Strasbourg, France, 67091
Contact: Julie HELMS, MD    33 3 69 55 13 69    julie.helms@chru-strasbourg.fr   
Contact: Thierry ARTZNER, MD    33 3 69 55 13 69    Thierry.artzner@chru-strasbourg.fr   
Principal Investigator: Julie HELMS, MD         
Sub-Investigator: Thierry ARTZNER, MD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Layout table for investigator information
Study Director: Julie HELMS, MD University Hospital, Strasbourg, France
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT03452631    
Other Study ID Numbers: 6838
First Posted: March 2, 2018    Key Record Dates
Last Update Posted: July 6, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Strasbourg, France:
Psoas hematomas
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematoma
Hemorrhage
Pathologic Processes